<DOC>
	<DOCNO>NCT00103740</DOCNO>
	<brief_summary>The primary objective core study show non-inferiority zoledronic acid risedronate , respect proportion patient achieve therapeutic response . The extended observation period include participant core study respond treatment .</brief_summary>
	<brief_title>Safety Efficacy Trial With Zoledronic Acid Treatment Paget 's Disease Bone , Including Extended Observation Period</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Osteitis Deformans</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>30 year old SAP 2 time ULN Confirmed diagnosis Paget 's disease bone ( xray , magnetic resonance imaging , computerized tomography , radioisotope imaging , etc. ) . 90 day washout calcitonin 180 day washout bisphosphonate Allergic reaction bisphosphonates History upper GI disorder History iritis , uveitis Calculated creatinine clearance &lt; 30 ml/min baseline Evidence vitamin D deficiency Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Zoledronic acid , risedronate , Paget 's disease bone</keyword>
</DOC>